For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240320:nRST6424Ha&default-theme=true
RNS Number : 6424H BSF Enterprise PLC 20 March 2024
20 March 2024
BSF Enterprise PLC
("BSF" or the "Company")
Result of Annual General Meeting
BSF Enterprise (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech
company and owner of pioneering UK-based tissue engineering company 3D
Bio-Tissues Ltd (3DBT) and corneal tissue replacement company Kerato Ltd, is
pleased to announce that at the Company's Annual General Meeting held earlier
today, all resolutions proposed were duly passed by shareholders by way of a
poll, the results of which were as follows:
Resolution Poll Results
For Against Withheld Discretionary Total
1 Shares 52,426,227 - - - 52,426,227
% 100.00% - - - 100%
2 Shares 52,421,227 5,000 - - 52,426,227
% 99.99% 0.01% - - 100%
3 Shares 52,421,227 5,000 - - 52,426,227
% 99.99% 0.01% - - 100%
4 Shares 52,426,227 - - - 52,426,227
% 100.00% - - 100%
5 Shares 46,646,377 - 5,779,850 - 52,426,227
% 88.98% - 11.02% - 100%
6 Shares 52,426,227 - - - 52,426,227
% 100.00% - - - 100%
7 Shares 52,402,826 23,401 - - 52,426,227
% 99.96% 0.04% - - 100%
8 Shares 52,421,227 - 5,000 - 52,426,227
% 99.99% - 0.01% 100%
9 Shares 52,397,826 23,401 5,000 - 52,426,227
% 99.95% 0.04% 0.01% - 100%
About BSF Enterprise PLC:
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cellbased tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas for testing to
help restore vision to millions of people. Building on this success, it aims
to produce the UK's first high quality leather from its laboratory in
Newcastle, transforming the leather industry towards an ethical and
sustainable practice.
BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to develop a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.
For further enquiries, please visit www.bsfenterprise.com or contact:
BSF Enterprise PLC Via SEC Newgate below
Geoff Baker - Executive Director
Che Connon - CEO & Director
Shard Capital (Broker)
Damon Heath 0207 186 9000
Isabella Pierre
0207 186 9927
SEC Newgate (Financial Communications)
Bob Huxford 020 3757 6882
Elisabeth Cowell BSF@secnewgate.co.uk
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGURVURSVUOUAR